Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women
European Journal of Epidemiology · 2023
DOI: 10.1007/s10654-023-00976-8 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift European Journal of Epidemiology, 2023. Verfasst von Lukas Løfling und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Cancer Registry of Norway, Postboks 5313 Majorstuen, 0304, Oslo, Norway. Hauptthemen laut MEDLINE: Aspirin, Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norwegian Research Council, University of Oslo.
Abstract (Originalsprache)
Several studies evaluated the association between aspirin use and risk of breast cancer (BC), with inconsistent results. We identified women aged ≥ 50 years residing in Norway between 2004 and 2018, and linked data from nationwide registries; including the Cancer Registry of Norway, the Norwegian Prescription Database, and national health surveys. We used Cox regression models to estimate the association between low-dose aspirin use and BC risk, overall and by BC characteristics, women’s age and body mass index (BMI), adjusting for sociodemographic factors and use of other medications. We included 1,083,629 women. During a median follow-up of 11.6 years, 257,442 (24%) women used aspirin, and 29,533 (3%) BCs occurred. For current use of aspirin, compared to never use, we found an indication of a reduced risk of oestrogen receptor-positive (ER +) BC (hazard ratio [HR] = 0.96, 95% confidence interval [CI]: 0.92–1.00), but not ER-negative BC (HR = 1.01, 95%CI: 0.90–1.13). The association with ER + BC was only found in women aged ≥ 65 years (HR = 0.95, 95%CI: 0.90–0.99), and became stronger as the duration of use increased (use of ≥ 4 years HR = 0.91, 95%CI: 0.85–0.98). BMI was available for 450,080 (42%) women. Current use of aspirin was associated with a reduced risk of ER + BC in women with BMI ≥ 25 (HR = 0.91, 95%CI: 0.83–0.99; HR = 0.86, 95%CI: 0.75–0.97 for use of ≥ 4 years), but not in women with BMI < 25.Use of low-dose aspirin was associated with reduced risk of ER + BC, in particular in women aged ≥ 65 years and overweight women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research, Cancer Registry of Norway, Postboks 5313 Majorstuen, 0304, Oslo, Norway.
- Norwegian Research Centre for Women's Health, Women's Clinic, Oslo University Hospital, Oslo, Norway.
- Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
- Cancer Registry of Norway, Oslo, Norway.
- Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
- Department of Preventive Medicine, University of Southern California, Los Angeles, USA.
Förderung
- Norwegian Research Council
- University of Oslo
Zitieren
APA
Løfling, L., Støer, N. C., Nafisi, S., Ursin, G., Hofvind, S., & Botteri, E. (2023). Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women. European Journal of Epidemiology. https://doi.org/10.1007/s10654-023-00976-8
Vancouver
Løfling L, Støer NC, Nafisi S, Ursin G, Hofvind S, Botteri E. Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women. European Journal of Epidemiology. 2023. doi:10.1007/s10654-023-00976-8
BibTeX
@article{Lfling2023,
author = {Løfling, Lukas and Støer, Nathalie C and Nafisi, Sara and Ursin, Giske and Hofvind, Solveig and Botteri, Edoardo},
title = {Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women},
journal = {European Journal of Epidemiology},
year = {2023},
doi = {10.1007/s10654-023-00976-8}
}
EUVIMED